Safety and Efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the Phase 2 STRIDE study

Liu JY, Scumpia P, Ni C, Yashar S, Langevin K, Kang Y, Vandiver A. A diagnostically challenging case of pemphigus foliaceus without histologic evidence of[...]

Kasperkiewicz M, Adotama P, Tomayko MM, Culton DA. Response to Barnawi et al., "Bullous pemphigoid in the era of immunotherapy: Implications for treatment algorithms". J[...]

Zhang H, Patrick MT, Sarkar MK, Bogle R, Li Q, Uppala R, Perez White BE, Petukhova L, Dand N, Stuart PE, Christiano AM, Simpson MA,[...]